Dolutegravir and rilpivirine tablets instructions for use

Update: 30 October, 2023

Dolutegravir and rilpivirine tablets instructions for use, for the treatment of adult human immunodeficiency virus type 1 (HIV-1) infection in patients who have achieved virologic suppression (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral treatment regimen for at least six months, have no history of virologic failure, and have no known or suspected resistance to non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

---

File format: PDF

Size: -

MD5 Checksum: 848E771867017055386FEB48952A4DC0

Publication date: 30 October, 2023

Downloads: -

PDF Link: Dolutegravir and rilpivirine tablets instructions for use PDF